Stratification of Candidates for Induction Chemotherapy in Stage III-IV Nasopharyngeal Carcinoma: A Large Cohort Study Based on a Comprehensive Prognostic Model

Xue-Song Sun 1,2†, Bei-Bei Xiao 1,2†, Zi-Jian Lu 1,2†, Sai-Lan Liu 1,2, Qiu-Yan Chen 1,2, Li Yuan 1, Lin-Quan Tang 1,2* and Hai-Qiang Mai 1,2*

1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China, 2 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China

Objective: To establish a prognostic index (PI) for patients with stage III-IV nasopharyngeal carcinoma (NPC) patients to personalize recommendations for induction chemotherapy (IC) before intensity-modulated radiotherapy (IMRT).

Patients and Methods: Patients received concurrent chemoradiotherapy (CCRT) with or without IC. Factors used to construct the PI were selected by a multivariate analysis of progression-free survival (PFS), which was the primary endpoint ($P < 0.05$). Five variables were selected based on a backward procedure in a Cox proportional hazards model: gender, T stage, N stage, lactate dehydrogenase (LDH), and Epstein–Barr virus (EBV) DNA. The cutoff value for the PI was determined by the receiver operating characteristic curve analysis.

Results: The present study involved 3,586 patients diagnosed with stage III-IV NPC. The cutoff value for PI was 0.8. The high-risk subgroup showed worse outcomes than did the low-risk subgroup on all endpoints: PFS, overall survival (OS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS). In the low-risk subgroup (PI $< 0.8$), patients showed comparable survival outcomes on all clinical endpoints regardless of IC application, whereas in the high-risk subgroup (PI $> 0.8$), the addition of IC significantly improved PFS, OS, and DMFS, but not LRFS. In multivariate analyses, IC was a protective factor for PFS, OS, and DMFS in the high-risk subgroup, while it had no significant benefit in the low-risk subgroup.

Conclusion: The proposed prognostic model effectively stratifies patients with stage III-IV NPC. High-risk patients are candidates for IC before CCRT, while low-risk patients are unlikely to benefit from it.

Keywords: nasopharyngeal carcinoma, Epstein–Barr virus DNA, induction chemotherapy, radiotherapy, survival
INTRODUCTION

Nasopharyngeal carcinoma (NPC), a malignant disease of the nasopharyngeal epithelium, has an incidence rate of 20–50 cases per 100,000 people in epidemic areas, such as Southeast Asia (1, 2). As NPC has high sensitivity to irradiation and a distinct anatomical location, radiotherapy (RT) is currently the only curative treatment for NPC. For stage I NPC, radiotherapy has been reported to achieve an overall survival (OS) rate of over 90%. For locoregionally advanced disease, which represents 70–90% of newly diagnosed NPC cases, radiotherapy with concurrent chemoradiotherapy (CCRT) could improve OS; thus, it is regarded as standard treatment (3–5). However, over 20% of patients still develop distant metastasis after CCRT (6).

By lowering tumor volume and restricting occult micrometastasis, induction chemotherapy (IC) before RT has been proposed to further decrease distant metastasis risk. Previous studies have shown that IC might improve survival outcomes in patients with locoregionally advanced NPC (7, 8). Nevertheless, not all patients with locoregionally advanced NPC benefit from IC. Previous studies have reported that IC might not improve survival among patients with T3-4N0-1 NPC; in fact, IC has been associated with severe toxicity in this patient group (9, 10). Given the body of evidence, it is likely that patients at high risk might benefit from IC more than patients at low risk. As such, a prognostic score to differentiate high- and low-risk patients is required to assist in clinical decision-making.

The tumor, node, metastasis (TNM) staging system, which continues to be a globally recognized standard for assessing the prognosis of NPC, has been criticized as barely satisfactory, as it does not account for important prognostic factors, such as Epstein–Barr virus (EBV) DNA and serum lactate dehydrogenase (LDH) levels (11–13). Therefore, this study aimed to evaluate several potential prognostic factors and construct a prognostic score to classify risk status and identify suitable patients with stage III-IVa NPC that could benefit from IC, using data from a large cohort of patients.

MATERIALS AND METHODS

Patients

This study included 3,586 stage III-IVa NPC patients treated at Sun Yat-sen University Cancer Center (SYSUCC) from January 2008 to December 2013 who met the following inclusion criteria: (1) biopsy-confirmed NPC; (2) non-metastasis status at diagnosis; (3) stage III-IVa NPC, based on the 8th edition of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system; (4) no history of malignancy or synchronous cancer; (5) complete clinicopathological and treatment information; (6) treatment with IC + CCRT or CCRT alone. The study protocol was approved by the clinical research ethics committee of our cancer center, and written informed consent was obtained from each patient. The flowchart capturing patient inclusion process is shown in Figure 1.

Quantification of Plasma EBV DNA Levels

Plasma EBV DNA quantification method is described in the Supplementary Material.

Treatment

In our cohort, 2077 patients were treated with CCRT alone and 1509 patients were treated with IC before CCRT. The common IC regimens were cisplatin (80 mg/m²) with 5-fluorouracil (800 mg/m²) and etoposide (100 mg/m²) with cisplatin (80 mg/m²) (6–8). The median number of cycles of IC was 4 (range: 1–6) in the cisplatin (80 mg/m²) with 5-fluorouracil (800 mg/m²) arm, and 3 (range: 1–5) in the cisplatin (80 mg/m²) with etoposide (100 mg/m²) arm. The IC regimen in the cisplatin (80 mg/m²) with etoposide (100 mg/m²) arm was changed during the study, and the clinical decision to make this change was based on the toxicity profile observed during the study. For the patients who tolerated the cisplatin (80 mg/m²) with etoposide (100 mg/m²) regimen, the chemotherapy was continued for a maximum of 6 cycles. For patients who developed severe toxicity, the chemotherapy was changed to cisplatin (80 mg/m²) with etoposide (100 mg/m²) combined with 5-fluorouracil (900 mg/m²) and mitomycin C (10 mg/m²). The median follow-up time was 56 months (range: 1–120 months).

FIGURE 1 | Flowchart presenting patient inclusion process.
mg/m²/day over 120 h), or cisplatin (80 mg/m²) with docetaxel (80 mg/m²), or cisplatin (60 mg/m²) with 5-fluorouracil (600 mg/m² over 120 h), and docetaxel (60 mg/m²) administered at 3-week intervals. Concurrent chemotherapy consisted of cisplatin/nedaplatin (80 or 100 mg/m²) given in Week 1, 4, and 7 of radiotherapy, or cisplatin/nedaplatin (40 mg/m²) given weekly during radiotherapy, beginning on the first day of radiotherapy. The radiotherapy technique used was intensity-modulated radiotherapy (IMRT), with 66–70 Gy to the primary radiotherapy. The radiotherapy technique used was intensity-modulated radiotherapy (IMRT), with 66–70 Gy to the primary

Follow-Up
All patients received comprehensive follow-up examinations every 3 months for the first 3 years and every 6 months thereafter.

Follow-up examinations included semiannual quantitative EBV DNA determination, nasopharyngoscopy, head and neck magnetic resonance imaging, chest radiography, and abdominal sonography. If locoregional relapse and/or distant metastasis were suspected, a bone scan, or 18F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT) were considered.

The primary endpoint of the present study was progression-free survival (PFS), which represented the time interval between first diagnosis and disease progression or death from any

| TABLE 1 | Baseline characteristics of patients in the CCRT and CCRT + IC groups. |
|----------|-----------------|-----------------|-----------------|-----------------|
| Characteristic | CCRT n (%) | CCRT + IC n (%) | P-value |
| Total | 2,077 | 1,509 | |
| Age, y | | | |
| ≤46 | 1,009 (48.6) | 769 (51.0) | 0.166 |
| >46 | 1,068 (51.4) | 740 (49.0) | |
| Gender | | | |
| Female | 552 (26.6) | 354 (23.5) | 0.036 |
| Male | 1,525 (73.4) | 1,155 (76.5) | |
| Diabetes mellitus | | | |
| No | 2,014 (97.0) | 1,480 (98.1) | 0.042 |
| Yes | 63 (3.0) | 29 (1.9) | |
| Cardiovascular disease | | | |
| No | 1,957 (94.2) | 1,431 (94.8) | 0.459 |
| Yes | 120 (5.8) | 78 (5.2) | |
| T stage | | | |
| T1 | 69 (3.3) | 45 (3.0) | <0.001 |
| T2 | 232 (11.2) | 181 (12.0) | |
| T3 | 1,365 (65.7) | 740 (49.0) | |
| T4 | 411 (19.8) | 543 (36.0) | |
| N stage | | | |
| N0 | 328 (15.8) | 135 (8.9) | <0.001 |
| N1 | 759 (36.5) | 433 (28.7) | |
| N2 | 967 (41.7) | 710 (47.1) | |
| N3 | 123 (5.9) | 231 (15.3) | |
| LDH level | | | |
| ≤245 U/L | 1,981 (95.4) | 1,399 (92.7) | 0.001 |
| >245 U/L | 96 (4.6) | 110 (7.3) | |
| EBV DNA level | | | |
| ≤1,500 copies/ml | 913 (44.0) | 425 (28.2) | <0.001 |
| >1,500 copies/ml | 1,164 (56.0) | 1,084 (71.8) | |

Follow-up examinations included semiannual quantitative EBV DNA determination, nasopharyngoscopy, head and neck magnetic resonance imaging, chest radiography, and abdominal sonography. If locoregional relapse and/or distant metastasis were suspected, a bone scan, or 18F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT) were considered.

The primary endpoint of the present study was progression-free survival (PFS), which represented the time interval between first diagnosis and disease progression or death from any

| TABLE 2 | Multivariable analysis of prognostic factors for progression-free survival, overall survival, locoregional relapse–free survival, and distant metastasis–free survival. |
|----------|-----------------|-----------------|-----------------|-----------------|
| Characteristic | HR | 95%CI | P value |
| Progression-free survival | | | |
| Gender | 1.369 | 1.113–1.684 | 0.003 |
| T stage | 1.441 | 1.200–1.729 | <0.001 |
| N stage | | | |
| N2 vs. N0-1 | 1.375 | 1.138–1.661 | <0.001 |
| N3 vs. N0-1 | 1.925 | 1.468–2.525 | <0.001 |
| LDH level | 1.414 | 1.055–1.897 | 0.021 |
| EBV-DNA level | 2.115 | 1.706–2.621 | <0.001 |
| Treatment method | 0.761 | 0.640–0.905 | 0.002 |
| Overall survival | | | |
| Age | 1.447 | 1.146–1.827 | 0.002 |
| Gender | 1.993 | 1.442–2.755 | <0.001 |
| T stage | 1.648 | 1.296–2.111 | <0.001 |
| N stage | | | |
| N2 vs. N0-1 | 1.679 | 1.290–2.187 | <0.001 |
| N3 vs. N0-1 | 2.468 | 1.692–3.599 | <0.001 |
| EBV-DNA level | 2.330 | 1.703–3.189 | <0.001 |
| Treatment method | 0.552 | 0.431–0.706 | <0.001 |
| Locoregional relapse–free survival | | | |
| T stage | 1.544 | 1.151–2.074 | 0.004 |
| EBV-DNA level | 2.102 | 1.486–2.971 | <0.001 |
| Distant metastasis–free survival | | | |
| Gender | 1.754 | 1.336–2.302 | <0.001 |
| Diabetes mellitus | 1.622 | 0.982–2.680 | 0.059 |
| T stage | 1.360 | 1.088–1.701 | 0.007 |
| N stage | | | |
| N2 vs. N0-1 | 1.434 | 1.134–1.813 | 0.003 |
| N3 vs. N0-1 | 2.491 | 1.818–3.413 | <0.001 |
| EBV-DNA level | 1.435 | 1.014–2.031 | 0.041 |
| LDH level | 2.378 | 1.813–3.119 | <0.001 |
| Treatment method | 0.651 | 0.526–0.805 | <0.001 |

HR, hazard ratio; CI, confidence interval; NPC, nasopharyngeal carcinoma; LDH, lactate dehydrogenase; EBV, Epstein–Barr virus. A Cox proportional hazards model was used to perform multivariate analyses. All variables were transformed into categorical variables. HRs were calculated for age (years) (≥46 vs. <46), gender (male vs. female), diabetes mellitus (yes vs. no), cardiovascular disease (yes vs. no), T stage (T4 vs. T1-3), LDH level (≥245 U/L vs. <245 U/L), EBV-DNA level (≥1,500 copies/ml vs. <1,500 copies/ml) and treatment method (CCRT + IC vs. CCRT). We selected variables using a backward stepwise approach. The P-value threshold was 0.1 (P < 0.1) for removing non-significant variables from the model.
cause. The following survival outcomes were secondary study endpoints: overall survival (OS) was defined as the time interval from the first diagnosis to death from any cause, while locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were defined as time from diagnosis to disease relapse in the nasopharynx or a neck lymph node, and to occurrence of distant metastasis, respectively. Patients lost to follow-up or alive without distant metastasis or locoregional recurrence at the last follow-up visit had their data censored.

Statistical Analysis
The patients' clinical characteristics and acute toxicity status were compared between treatment groups using the Pearson χ²-test or Fisher's exact test. Kaplan-Meier curves were used to compare survival outcomes between study groups with a log-rank test. All variables were transformed into categorical variables. A Cox proportional hazards model with a backward method was used for multivariate analyses. Covariates that were statistically significant (P < 0.05) were selected to construct the PI. The cohort was divided into low- and high-risk subgroups by the cutoff value of the PI score, which was determined by a receiver operating characteristic (ROC) curve. All statistical analyses were conducted using SPSS v23 (IBM, Armonk, IL, USA).

RESULTS
Patients' Characteristics and Survival
From January 2008 to December 2013, 3586 patients were involved in this study. Then median age of our cohort at diagnosis was 46 years; 74.7% of patients were men. In total, 1509 patients (42.1%) received IC before CCRT. Patient characteristics by treatment group are shown in Table 1. Patients with stage T4 or N2-3 disease were more likely to receive IC than were patients with stage T1-3 (P < 0.001) or N0-1 (P < 0.001) disease. Male gender (P = 0.036), higher (>245 U/L) level of LDH (P = 0.001), and pretreatment EBV DNA >1,500 copies/ml (P < 0.001) were also significantly associated with IC treatment. During a median follow-up time of 44.9 months (interquartile range 32.8–61.9 months), 299 patients (8.3%) died. The OS rates at 3 and 5 years were 94.0 and 88.9%, respectively.

Prognostic Factors and Establishment of the Prognostic Index
In multivariate analysis, gender [hazard ratio (HR) = 1.369; 95% confidence interval (CI) = 1.113–1.684; P = 0.003], T stage (HR = 1.441; 95% CI = 1.200–1.729; P < 0.001), N stage (N2 vs. N0-1: HR = 1.375; 95% CI = 1.138–1.661; P = 0.001; N3 vs. N0-1: HR = 1.925; 95% CI = 1.468–2.525; P < 0.001), LDH level (HR = 1.414; 95% CI = 1.055–1.897; P = 0.021), and EBV DNA level (HR = 2.115; 95% CI = 1.706–2.621; P < 0.001) emerged as independent prognostic factors for PFS (Table 2). Subsequently, the PI was constructed based on weighting (derived by the log [adjusted HR]) of these five prognostic factors (Table 3). The results of multivariate analysis in terms of OS, LRFS, and DMFS are also shown in Table 2.

Risk Stratification
Using this PI model, we divided patients into low- and high-risk subgroups. The cutoff value was PI = 0.8, determined by the ROC analysis. Clinical characteristics of patients in two risk subgroups are shown in Table 4. Patients with lower PI (low-risk) achieved a significantly greater PFS compared with high-risk patients (3-year PFS rate: 92.1% vs. 81.7%; P < 0.001). A similar association was found for OS, LRFS, and DMFS (3-year OS rate: 97.8% vs. 91.7%; P < 0.001; 3-year LRFS rate: 97.1% vs. 94.2%; P < 0.001; 3-year DMFS rate: 95.3% vs. 86.5%; P < 0.001; Figures 2A–D).

The Efficacy of IC in Risk-Based Subgroups
Given that patients in different risk subgroups were likely to suffer different tumor burden, we investigated the efficacy of IC in low- and high-risk patients and found that it differed between the subgroups. In the low-risk subgroup (PI < 0.8), non-significant differences were observed in PFS (P = 0.422), OS (P = 0.100), LRFS (P = 0.455), and DMFS (P = 0.662) between the IC + CCRT and CCRT groups (Figures 3A-D). However, in the high-risk subgroup, patients receiving IC + CCRT achieved greater PFS, OS, and DMFS than did patients receiving CCRT alone (3-year PFS rate: 83.5% vs. 77.9%, P = 0.012; 3-year OS rate: 94.0 vs. 89.4%, P < 0.001; 3-year DMFS rate: 88.6 vs. 84.2%, P = 0.003). There was no significant difference between two treatment groups in LRFS (Figures 4A–D).

In multivariate analysis, within the low-risk subgroup, there was no significant survival difference between two treatment groups.

### Table 3 | Prognostic score to predict progression-free survival.

| Variable | Hazard ratio | Score [HR = exp (score)] |
|----------|--------------|--------------------------|
| Gender   | Male         | 1.369                    | 0.314 |
| T stage ≥3 | T1-3         | 1                        | 0     |
|          | T4           | 1.441                    | 0.365 |
| N stage ≥3 | N0-1         | 1                        | 0     |
|          | N2           | 1.375                    | 0.318 |
|          | N3           | 1.925                    | 0.655 |
| LDH level ≤245 U/L | 1  | 0     |
|          | >245 U/L     | 1.414                    | 0.346 |
| EBV-DNA level ≤1500 copies/ml | 1  | 0     |
|          | >1500 copies/ml | 2.115                | 0.749 |

Hazard ratios were estimated by a Cox proportional hazards regression. 

| Variable | Hazard ratio | Score [HR = exp (score)] |
|----------|--------------|--------------------------|
| Gender   | Male         | 1.369                    | 0.314 |
| T stage ≥3 | T1-3         | 1                        | 0     |
|          | T4           | 1.441                    | 0.365 |
| N stage ≥3 | N0-1         | 1                        | 0     |
|          | N2           | 1.375                    | 0.318 |
|          | N3           | 1.925                    | 0.655 |
| LDH level ≤245 U/L | 1  | 0     |
|          | >245 U/L     | 1.414                    | 0.346 |
| EBV-DNA level ≤1500 copies/ml | 1  | 0     |
|          | >1500 copies/ml | 2.115                | 0.749 |

Hazard ratios were estimated by a Cox proportional hazards regression. 

According to the 8th edition of the UICC/AJCC staging system.
TABLE 4 Clinical characteristics of patients in low- and high-risk subgroups.

| Characteristic        | Low-risk patients n (%) | High-risk patients n (%) | P-value |
|-----------------------|--------------------------|--------------------------|---------|
|                       | CCRT                     | CCRT + IC                |         |
| Total                 | 972                      | 414                      |         |
|                       | 1,105                    | 1,095                    |         |
| Age, y                |                          |                          |         |
| ≤46                   | 503 (51.7)               | 224 (54.1)               | 0.445   |
| >46                   | 469 (48.3)               | 190 (45.9)               |         |
| Gender                |                          |                          |         |
| Female                | 357 (36.7)               | 143 (34.5)               | 0.464   |
| Male                  | 615 (63.3)               | 271 (65.5)               |         |
| Diabetes mellitus     |                          |                          |         |
| No                    | 943 (97.0)               | 408 (98.6)               | 0.097   |
| Yes                   | 29 (3.0)                 | 6 (1.4)                  |         |
| Cardiovascular disease|                          |                          |         |
| No                    | 911 (93.7)               | 400 (96.6)               | 0.028   |
| Yes                   | 61 (6.3)                 | 14 (3.4)                 |         |
| T stage<sup>a</sup>   |                          |                          |         |
| T1                    | 26 (2.7)                 | 6 (1.4)                  | <0.001  |
| T2                    | 69 (7.1)                 | 40 (9.7)                 |         |
| T3                    | 762 (78.4)               | 247 (59.7)               |         |
| T4                    | 115 (11.8)               | 121 (29.2)               |         |
| N stage<sup>a</sup>   |                          |                          |         |
| N0                    | 262 (27.0)               | 77 (18.6)                | 0.005   |
| N1                    | 456 (46.9)               | 204 (49.3)               |         |
| N2                    | 241 (24.8)               | 125 (30.2)               |         |
| N3                    | 13 (1.3)                 | 8 (1.9)                  |         |
| LDH level             |                          |                          |         |
| ≤245 U/L              | 957 (98.5)               | 410 (99.0)               | 0.462   |
| >245 U/L              | 15 (1.5)                 | 4 (1.0)                  |         |
| EBV DNA level         |                          |                          |         |
| ≤1,500 copies/ml      | 880 (90.5)               | 371 (89.6)               | 0.621   |
| >1,500 copies/ml      | 92 (9.5)                 | 43 (10.4)                |         |

CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; LDH, lactate dehydrogenase; EBV, Epstein–Barr virus.

<sup>a</sup>According to the 8th edition of the UICC/AJCC staging system.

P-values were calculated by a χ<sup>2</sup>-test.

groups (P > 0.05 for all survival endpoints). In contrast, in the high-risk subgroup, the addition of IC was found to be protective for PFS (HR = 0.709; 95% CI, 0.585–0.858; P = 0.002), OS (HR = 0.466; 95% CI = 0.356–0.610; P < 0.001), and DMFS (HR = 0.633; 95% CI = 0.502–0.797; P < 0.001). There was no effect for LRFS (Table 5).

**Acute Toxicity**

Details of treatment-related acute toxicity experienced by patients receiving CCRT and CCRT + IC are presented in Table 6. The IC + CCRT group had a significantly higher proportion of grade 3–4 leukopenia (30.0 vs. 16.3%; P < 0.001) and neutropenia (37.8 vs. 15.2%; P < 0.001) than did the CCRT alone group. Between-group differences in other hematological toxicities, such as anemia or thrombocytopenia, were not significant. No significant differences in grade 3–4 hepatotoxicity or nephrotoxicity were observed between the treatment groups.

**DISCUSSION**

The present study identified independent prognostic factors for patients with stage III-IVa NPC in the IMRT era. Our study involved a large cohort and development of a PI to personalize treatment recommendations for IC. For patient stratification, the PI cutoff value was determined by the ROC analysis. We found that high-risk patients are likely to benefit from the addition of IC before CCRT, whereas low-risk patients are unlikely to benefit from it.

CCRT is standard treatment for locoregionally advanced NPC. As radiotherapy technology has developed, the local control rate of NPC has improved significantly (15). In
the IMRT era, occurrence of distant metastasis has become the predominant sign of failed treatment (16, 17). Recently, several clinical trials have provided evidence that IC before definitive CCRT is associated with lower incidence of distant metastases and further improved patient survival (7, 18, 19). However, according to studies among patients with stage T3-4 N0-1, clinical outcome was similar between the CCRT and IC + CCRT groups, indicating that IC might benefit only patients with a greater tumor burden (9, 10). Considering the toxicity and economic cost of chemotherapy, it is important to identify suitable patients who could benefit from additional IC.

The current AJCC/UICC stage classification is the main guideline for NPC risk stratification in clinical practice. However, this classification does not consider several variables that have been suggested as prognostic factors in NPC, such as age, gender, LDH, comorbidities, and, in particular, EBV DNA (11–13). Therefore, a more comprehensive prognostic model is urgently needed to accurately predict patients’ clinical outcome.

In previous studies, several prognostic models were put forward to help select high-risk patients that might benefit from IC (20–22). Zhang et al. developed and validated a nomogram to predict individual benefit of IC based on a Phase III clinical trial (22). However, only 480 participants were involved in the establishment of the nomogram, and plasma EBV DNA was not included. Similarly, Du et al. created a prognostic model for distant metastasis in locally advanced NPC patients to identify high-risk patients who should receive IC, where the prognostic score was the sum of the number of prognostic factors (20). It was less rigorous in that different risk factors did not share the same weight in treatment failure. In our study, the PI scores were calculated based on the logarithm of HRs derived from multivariate analysis. To our knowledge, to-date, our study involved the largest cohort in establishing prognostic scores for selecting candidates for IC in stage III-IVa NPC.

We set PFS as the primary endpoint. In our results, five characteristics (gender, T stage, N stage, LDH level, and EBV DNA level) were selected and remained independent
factors in multivariate analysis. Previous studies have verified all five of these factors as important prognostic indicators (11). After the trade-off between sensitivity and specificity was resolved, the cutoff value of PI was determined as 0.8, with 1386 and 2200 patients identified as at low- and high-risk, respectively. Among patients with a higher PI, patients achieved a higher PFS rate, if they were in the IC + CCRT group. In contrast, no significant differences between the treatment groups were observed in the low-risk subgroup.

Collectively, our findings justify the recommendation of IC for patients identified as at high-risk, which could be explained by the following reasons. IC plays an important role in early eradication of tumor before radical radiotherapy. Patients in the high-risk subgroup suffer a greater tumor burden and higher risk of treatment failure. Some of them also might develop subclinical micrometastasis at diagnosis, which might indicate they should receive intensified therapy. Concurrently, induction chemotherapy can reduce tumor volume, which can support radiotherapy and shrink the target area. As a result, long-term toxicities, such as radiation encephalopathy, xerostomia, or trismus might improve to some extent. Therefore, the addition of IC could help these patients achieve longer disease-free survival. However, patients in the low-risk subgroup had a relatively satisfactory clinical outcome when treated with CCRT alone. Concurrently, additional toxic effects such as hepatotoxicity or nephrotoxicity caused by IC may influence the survival benefit.

Our study shows great potential for application in clinical practice. Clinicians could evaluate the condition of stage III-IVa NPC patients before treatment using our PI system and select high-risk patients who may benefit from IC. However, it should be noted that more than 10% of high-risk patients still developed distant lesions in the IC + CCRT group, suggesting that a more intense therapy such as targeted therapy may be necessary for this subgroup (23, 24).
group has launched a phase 1 study of tumor-infiltrating lymphocyte immunotherapy after CCRT in high-risk NPC; we were looking forward to the results of the phase 2 study (25).

Although this study is based on a large cohort, it has several limitations. First, it was a retrospective study, so survival outcomes might be affected by confounding factors, and accurate data on late toxicities could not be acquired. Secondly, the data were obtained from a single treatment center; therefore, our results should be validated by other datasets.

In conclusion, we proposed a PI model to predict whether patients could benefit from additional IC before CCRT and thereby to improve the decision-making process for patients with stage III-IVa NPC. Patients with higher PI (>0.8) are identified as at high-risk and would be likely to benefit from additional IC, whereas low-risk patients are unlikely to benefit from it.

DATA AVAILABILITY STATEMENT

The datasets analyzed in this article are not publicly available. Requests to access the datasets should be directed to maihq@mail.sysu.edu.cn.

ETHICS STATEMENT

This retrospective study was approved by the Clinical Research Committee of SYSUCC. Patients were required to provide written informed consent before enrolling in the study.

AUTHOR CONTRIBUTIONS

H-QM, L-QT, Q-YC, and LY: study concepts and manuscript review. X-SS, B-BX, Z-JL, and S-LL: study design, data acquisition, and data analysis and interpretation. X-SS, B-BX, and
TABLE 5 | Multivariate analysis of progression-free survival, overall survival, locoregional relapse-free survival, and distant metastasis-free survival in low- and high-risk subgroups.

| Characteristic          | Low-risk subgroup | High-risk subgroup |
|-------------------------|-------------------|-------------------|
|                         | HR                | 95% CI            | P-value | HR            | 95% CI           | P-value |
| **Progression-free survival** |                   |                   |         |               |                   |         |
| Gender                  | 1.833             | 1.083–3.103       | 0.024   | Gender        | 1.397            | 1.080–1.807 | 0.011   |
| T stage                 | 1.545             | 0.953–2.504       | 0.077   | T stage       | 1.427            | 1.164–1.749 | 0.001   |
| N stage                 |                   |                   |         | N stage       |                   |         |
| N1 vs. N0               | 1.079             | 0.672–1.731       | 0.754   | N1 vs. N0     | 1.486            | 1.182–1.867 | 0.001   |
| N2 vs. N0               | 6.441             | 2.307–19.988      | <0.001  | N2 vs. N0     | 1.938            | 1.428–2.631 | <0.001  |
| EBV DNA level           | 3.603             | 1.806–7.189       | <0.001  | EBV DNA level | 1.556            | 0.920–2.630 | 0.009   |
| **Overall survival**    |                   |                   |         |               |                   |         |
| Age                     | 1.810             | 0.993–3.299       | 0.053   | Age           | 1.351            | 1.048–1.741 | 0.020   |
| Gender                  | 5.075             | 1.557–16.537      | 0.007   | Gender        | 1.774            | 1.222–2.577 | 0.003   |
| Cardiovascular disease  | 2.787             | 1.22–6.365        | 0.015   | T stage       | 1.511            | 1.156–1.975 | 0.003   |
| T stage                 | 2.382             | 1.135–5.001       | 0.022   | N stage       |                   |         |
| N stage                 |                   |                   |         | N1 vs. N0     | 1.657            | 1.222–2.246 | 0.001   |
| N2 vs. N0               | 1.652             | 0.785–3.476       | 0.186   | N2 vs. N0     | 2.310            | 1.537–3.472 | <0.001  |
| EBV DNA level           | 11.017            | 1.882–112.183     | 0.043   | Treatment method | 0.486        | 0.356–0.610 | <0.001  |
| LDH level               | 9.119             | 2.154–38.612      | 0.003   |                   |                   |         |
| **Locoregional relapse-free survival** |                   |                   |         |               |                   |         |
| T stage                 | 1.961             | 0.990–3.887       | 0.054   | T stage       | 1.431            | 1.028–1.991 | 0.034   |
| EBV DNA level           | 2.331             | 1.055–5.149       | 0.036   |                   |                   |         |
| **Distant metastasis-free survival** |                   |                   |         |               |                   |         |
| Gender                  | 2.382             | 1.126–5.039       | 0.023   | Gender        | 1.840            | 1.309–2.586 | <0.001  |
| N stage                 |                   |                   |         | Diabetes mellitus | 1.791        | 1.063–3.015 | 0.028   |
| N2 vs. N0-1             | 1.072             | 0.606–1.897       | 0.812   | T stage       | 1.295            | 1.015–1.651 | 0.037   |
| N3 vs. N0-1             | 7.237             | 1.888–27.739      | 0.004   | N stage       |                   |         |
| EBV-DNA level           | 4.371             | 1.769–10.801      | 0.001   | N2 vs. N0-1   | 1.506            | 1.141–1.988 | 0.004   |
| LDH level               |                   |                   |         | N3 vs. N0-1   | 2.366            | 1.667–3.358 | <0.001  |
| Hepatotoxicity          |                   |                   |         | LDH level     | 1.425            | 1.001–2.028 | 0.050   |
| Nephrotoxicity          |                   |                   |         | Treatment method | 0.633        | 0.502–0.797 | <0.001  |

HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; EBV, Epstein–Barr virus; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy.

A Cox proportional hazards model was used to perform multivariate analyses. All variables were transformed into categorical variables. HRs were calculated for age (years) (>46 vs. ≤46), gender (male vs. female), diabetes mellitus (yes vs. no), cardiovascular disease (yes vs. no), T stage (T4 vs. T1-3), LDH level (>245 U/L vs. ≤245 U/L), EBV DNA level (>1,500 copies/ml vs. ≤1,500 copies/ml) and treatment method (CCRT + IC vs. CCRT).

We selected variables with a backward stepwise approach. The P-value threshold was 0.1 (P > 0.1) for removing non-significant variables from the model.

TABLE 6 | Acute toxicities in patients between CCRT and CCRT + IC groups.

| Adverse event (Toxicity grade) | CCRT (n = 2,077) | CCRT + IC (n = 1,509) |
|--------------------------------|------------------|-----------------------|
|                                | 0–2 (%)          | 3–4 (%)               | 0–2 (%) | 3–4 (%) | P-value |
| Leukocytopenia                 | 1,738 (83.7)     | 339 (16.3)            | 1,056 (70.0) | 453 (30.0) | <0.001 |
| Neutropenia                    | 1,761 (84.8)     | 316 (15.2)            | 939 (62.2) | 570 (37.8) | <0.001 |
| Anemia                         | 2,033 (97.9)     | 44 (2.1)              | 1,481 (98.2) | 28 (1.8) | 0.651 |
| Thrombocytopenia               | 2,052 (98.8)     | 25 (1.2)              | 1,484 (98.3) | 25 (1.7) | 0.313 |
| Hepatotoxicity                 | 2,054 (98.9)     | 23 (1.1)              | 1,482 (98.2) | 27 (1.8) | 0.112 |
| Nephrotoxicity                 | 2,077 (100.0)    | 0 (0.0)               | 1,507 (99.9) | 2 (0.1) | 0.177 a |

CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy.

aP-value was calculated with the Pearson χ²-test or Fisher's exact test.
Z-JL: quality control of data and algorithms, statistical analysis, and manuscript preparation and editing.

**FUNDING**

This work was supported by grants from the following organizations and institutions: National Key R&D Program of China (2017YFC1309003 and 2017YFC0908500), National Natural Science Foundation of China (Nos. 81425018, 81672686, and 81602371), Sun Yat-sen University Clinical Research 5010 Program (201707020039, 2014A020212103, and 16zyc02), Sci-Tech Project Foundation of Guangzhou City (201707020039), National Key Basic Research Program of China (No. 2013CB910304), Special Support Plan of Guangdong (201707020039), National Key Basic Research Program of China (2017YFC1309003 and 2017YFC0908500), and Central Universities Fundamental Research Funds the National Science Foundation of Guangdong Province for Distinguished Young Scholar (No. 2018B030306001), and Pearl River S&T Nova Program of Guangzhou (No. 201806010135).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00255/full#supplementary-material

**REFERENCES**

1. Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. CA Cancer J Clin. (2015) 65:87–108. doi: 10.3322/caac.21262
2. Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China 2013. Chin J Cancer. (2017) 36:90. doi: 10.1186/s40880-017-0257-9
3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. (2003) 21:651–7. doi: 10.1200/JCO.2003.08.158
4. Chan A, Teo P, Ngan R, Leung T, Lau W, Zee B, et al. Concurrent chemoradiation compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. (2002) 20:2038–44. doi: 10.1200/JCO.2002.08.149
5. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. (1998) 16:1310–17. doi: 10.1200/JCO.1998.16.4.1310
6. Wu F, Wang R, Lu H, Wei B, Feng G, Li G, et al. Concurrent chemoradiation in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol. (2014) 112:106–11. doi: 10.1016/j.radonc.2014.05.005
7. Sun Y, Li W, Chen N, Zhang N, Hu G, Xie F, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III, multicentre, randomised controlled trial. Lancet Oncol. (2016) 17:1509–20. doi: 10.1016/S1470-2045(16)30410-7
8. Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. (2018) 24:1824–33. doi: 10.1158/1078-0432.CCR-17-2656
9. Lan KW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-score matching study. Oncotarget. (2017) 8:76807–15. doi: 10.18632/oncotarget.20014
10. Wu LR, Yu HL, Jiang N, Jiang XS, Zong D, Wen J, et al. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. (2017) 10:3853–60. doi: 10.2147/OTT.S133917
11. Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. (2016) 108:dyw291. doi: 10.1093/jnci/dyw291
12. Peng XS, Xie GF, Qiu WZ, Tian YH, Zhang WJ, Cao KJ. Type 2 Diabetic mellitus is a risk factor for nasopharyngeal carcinoma: a 1:2 matched case-control study. PLoS ONE. (2016) 11:e0165131. doi: 10.1371/journal.pone.0165131
13. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. (2004) 350:2461–70. doi: 10.1056/NEJMoa032260
14. Yu Z, Luo W, Zhou QC, Zhang QH, Kang DH, Liu MZ. Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma. Ai zheng (2009), 28:1128–37. doi: 10.5732/cjic.009.10435
15. Zhang M, Li J, Shen G, Zou X, Xu J, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. (2015) 51:2587–95. doi: 10.1016/j.ejca.2015.08.006
16. Tang L, Chen Q, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. (2013) 31:2861–9. doi: 10.1200/JCO.2012.46.0816
17. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. (2014) 110:398–403. doi: 10.1016/j.radonc.2013.10.020
18. Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. (2017) 75:618–26. doi: 10.1016/j.ejca.2016.12.039
19. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gencitabin and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. (2019) 381:1124–35. doi: 10.1056/NEJMoa1905287
20. Du XJ, Tang LL, Chen L, Mao YP, Guo R, Liu X, et al. Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Sci Rep. (2015) 5:16664. doi: 10.1038/srep16664

City (No. 20140000001), National Science & Technology Pillar Program during the Twelfth 5-Year Plan Period (No. 2014BA109B10), Ph.D. Start-up Fund of the Natural Science Foundation of Guangdong Province (2016A030310221), cultivation foundation for the junior teachers in Sun Yat-sen University (16ykpy28), foundation for major projects and new cross subjects in Sun Yat-sen University (16ykjc38), Central Universities Fundamental Research Funds the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (No. 2018B030306001), and Pearl River S&T Nova Program of Guangzhou (No. 201806010135).
21. OuYang PY, Zhang LN, Xiao Y, Lan XW, Zhang XM, Ma J, et al. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. *Oral Oncol.* (2017) 67:37–45. doi: 10.1016/j.oraloncology.2017.01.009

22. Zhang Y, Li WF, Mao YP, Zhou GQ, Peng H, Sun Y, et al. Establishment of an integrated model incorporating standardised uptake value and N-classification for predicting metastasis in nasopharyngeal carcinoma. *Oncotarget.* (2016) 7:13612–20. doi: 10.18632/oncotarget.7253

23. Masmoudi A, Toumi N, Khanfir A, Kallel-Slimi L, Daoud J, Karray H, et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. *Cancer Treat Rev.* (2007) 33:499–505. doi: 10.1016/j.ctrv.2007.04.007

24. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. *Leuk Lymphoma.* (2005) 46:1–10. doi: 10.1080/10428190400002202

25. Li J, Chen Q, He J, Li Z, Tang X, Chen S, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. *Oncoimmunology.* (2015) e4:976507. doi: 10.4161/23723556.2014.976507

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a shared affiliation, though no other collaboration, with the authors.